129 results
Page 3 of 7
D
usn3orukr9wsaqdyp85b
4 Nov 21
Indefinite amount in equity, sold $67.26K, 6 investors
4:20pm
8-K
EX-2.1
g3ha5y 73
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
8-K
EX-10.1
ckjad7k3du36a noei5
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
D
uln zoebfoigl6f
23 Aug 21
$10.75M in options / securities to be acquired, sold $10.75M, 14 investors
4:15pm
8-K
EX-10.1
060oyz
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-10.1
z7i6ft 3yp
26 Jul 21
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer
4:18pm
8-K/A
EX-99.1
e079fqd
5 Mar 21
Financial Statements and Exhibits
4:15pm
8-K
EX-10.3
svqb uulta2le
1 Feb 21
Departure of Directors or Certain Officers
6:55am